z-logo
Premium
The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma
Author(s) -
Hecht Jonathan L.,
Lee Benjamin H.,
Pinkus Jack L.,
Pinkus Geraldine S.
Publication year - 2002
Publication title -
cancer cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.10482
Subject(s) - mesothelioma , medicine , wilms' tumor , wilms tumour , cytology , pathology , value (mathematics) , gene , oncology , genetics , biology , machine learning , computer science
BACKGROUND It has been shown that detection of the Wilms tumor susceptibility gene 1 protein (WT1) has diagnostic utility in the distinction of mesothelioma from adenocarcinoma in tissue sections of pleural tumors. This immunohistochemical study evaluates the effectiveness of WT1 as a marker for malignant mesothelioma in paraffin sections of cell block preparations derived from effusion specimens. METHODS The authors evaluated 111 cell blocks for WT1 immunoreactivity, including 14 mesotheliomas and 97 metastatic adenocarcinomas from various sites. RESULTS Nuclear reactivity for WT1 was observed in all samples of mesothelioma. However, only 22 of 97 samples (23%) of metastatic adenocarcinoma, nearly all of which were of ovarian origin (91%), exhibited nuclear reactivity for WT1. In 14 other samples (most of pulmonary derivation), WT1 staining restricted to the cytoplasm was observed for some tumor cells and was regarded as nonspecific. CONCLUSIONS Based on this staining profile, WT1 represents an effective marker for mesotheliomas in cell block preparations and can aid in its distinction from pulmonary adenocarcinoma. In assessment of effusion specimens with metastatic carcinoma, nuclear reactivity for WT1 is highly suggestive of an ovary primary tumor. Cancer (Cancer Cytopathol) 2002;96:000–000. © 2002 American Cancer Society.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here